Merck's heart failure drug misses trial goals

Jun 05, 2009

(AP) -- Merck and Co. said Friday its heart failure treatment rolofylline missed its goals in a trial, failing to improve patient symptoms compared with a placebo.

The company said rolofylline did not reach its primary or secondary goals in the late-stage trial. Based on the results, Merck said it no longer plans to ask the to approve the drug candidate this year.

The trial also showed that 30 mg of rolofylline did not reduce the risk of death or hospitalization due to heart or kidney problems 60 days after treatment, and that it did not reduce kidney impairment.

Merck is still analyzing study data from the study, which is called PROTECT, and it will present full results from the 2,033-patient trial at a medical conference later this year.

In morning trading, Merck shares fell 64 cents, or 2.4 percent, to $25.94.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Vaccine for West Nile Virus enters human clinical trials

Related Stories

FDA to review Vytorin results

Jan 26, 2008

The U.S. Food and Drug Administration said it is conducting a review of the cholesterol drug Vytorin based on preliminary results from a recent study.

Merck's Vioxx cases drag on

Aug 21, 2007

Lawsuits related to the painkiller Vioxx have little prospect of resolution for the thousands who have sued the drug company Merck, it was reported.

AstraZeneca, Merck collaborate on cancer treatment

Jun 01, 2009

(AP) -- AstraZeneca PLC and Merck & Co. said Monday they will jointly develop a pair of drugs meant to hit cancer with a one-two punch, part of a growing trend of combination cancer treatments.

Trials find no benefits of Zetia

Jan 15, 2008

The U.S. makers of the cholesterol-lowering drug Zetia say a clinical trial failed to identify any medical benefits of the medication.

Study: Vioxx poses even short-term risks

May 03, 2006

A Montreal study raises questions about even short-term use of the pain drug Vioxx and may harm Merck & Co.'s defense against 11,500 lawsuits, a report said.

FDA pans Merck's new pain pill

Apr 13, 2007

The U.S. Food and Drug Administration has rejected Merck's bid to sell the pain medication Arcoxia in the United States.

Recommended for you

Teva to lift bid for Mylan: report

10 hours ago

Israeli pharmaceutical giant Teva plans to increase its bid for rival Mylan and could announce the move as soon as this week, according to a US media report Monday.

Vaccine for West Nile Virus enters human clinical trials

14 hours ago

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ...

FDA clears drug for leading form of cystic fibrosis

Jul 02, 2015

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

deatopmg
1 / 5 (1) Jun 05, 2009
Did the silly study name reflect the outcome for the patients or the bottom line.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.